We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

INDV Indivior Plc

-6.00 (-0.35%)
28 Feb 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Indivior Plc LSE:INDV London Ordinary Share GB00BN4HT335 ORD USD0.50
  Price Change % Change Share Price Shares Traded Last Trade
  -6.00 -0.35% 1,719.00 469,802 16:35:03
Bid Price Offer Price High Price Low Price Open Price
1,716.00 1,720.00 1,745.00 1,702.00 1,727.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations USD 901M USD -53M USD -0.3844 -44.75 2.37B
Last Trade Time Trade Type Trade Size Trade Price Currency
18:03:08 O 5,755 1,713.593 GBX

Indivior (INDV) Latest News

Indivior (INDV) Discussions and Chat

Indivior Forums and Chat

Date Time Title Posts
09/3/202010:34RB. de-merger 548
11/7/201907:29Johnson & Johnson court case oklahoma6
03/5/201909:16Judgement against insys2
31/7/201812:45Indivior (INDV) IP Battle Status -

Add a New Thread

Indivior (INDV) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

Indivior (INDV) Top Chat Posts

Top Posts
Posted at 28/2/2024 08:20 by Indivior Daily Update
Indivior Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker INDV. The last closing price for Indivior was 1,725p.
Indivior currently has 137,878,579 shares in issue. The market capitalisation of Indivior is £2,371,511,559.
Indivior has a price to earnings ratio (PE ratio) of -44.75.
This morning INDV shares opened at 1,727p
Posted at 23/2/2024 11:13 by porsche1945
Getting out of brexit basket case U.K. with a US listing will be worth a 30/40 pc share price rise and also gives dollar protection as sterling now in perma-decline, good move.
Posted at 22/2/2024 13:19 by casholaa
Fentanyl use is rising, so I take this to mean that the market for indv also increases.
Posted at 22/2/2024 13:13 by adrian j boris

There are certain ongoing legal proceedings or threats of legal proceedings in which the Group is a party, but in which the Group believes the possibility of an adverse impact is remote and they are not discussed in this Note.

Antitrust Litigation and Consumer Protection

Multidistrict Antitrust Class and State Claims

• Indivior Inc. has entered into settlement agreements to resolve all claims of all plaintiff groups in the company's previously-disclosed antitrust multidistrict litigation ("Antitrust MDL"). In the Antitrust MDL, civil antitrust claims had been filed by three classes of Plaintiffs -namely, (i) 41 states and the District of Columbia (the "States"), (ii) end payors, and (iii) direct purchasers (collectively, the "Plaintiffs"). The Plaintiffs generally alleged, among other things, that Reckitt Benckiser Pharmaceuticals Inc. ("RBPI," now known as Indivior Inc.) violated U.S. federal and/or state antitrust and consumer protection laws in attempting to delay generic entry of alternatives to SUBOXONE Tablets. Plaintiffs further alleged that RBPI unlawfully acted to lower the market share of these products.

• After engaging in informal settlement discussions and formal mediation, Indivior Inc. reached a settlement with the States for $103m on June 1, 2023. Indivior Inc. entered into a settlement agreement with the end payor class for $30m on August 14, 2023 and received final court approval on December 5, 2023. On October 22, 2023, Indivior Inc. entered into a settlement agreement with the remaining direct purchaser class for $385m. The direct purchaser settlement has been preliminarily approved by the Court and remains subject to a notice period and final approval by the Court. A fairness hearing concerning the direct purchaser settlement is set for February 27, 2024.

Other Antitrust and Consumer Protection Claims

• In 2013, RBPI (now known as Indivior Inc.) received notice that it and other companies were defendants in a lawsuit initiated by writ in the Philadelphia County (Pennsylvania) Court of Common Pleas. See Carefirst of Maryland, Inc. et al. v. Reckitt Benckiser Inc., et al., Case. No. 2875, December Term 2013. The plaintiffs included approximately 79 entities, most of which appeared to be insurance companies or other providers of health benefits plans. The Carefirst plaintiffs' claims were resolved in connection with final approval of the end payor settlement in the Antitrust MDL, and the Carefirst action accordingly was dismissed on February 14, 2024.

• Humana, Inc. filed a Complaint in state court in Kentucky on August 20, 2021 with substantially the same claims as were raised in the Antitrust MDL. See Humana Inc. v. Indivior Inc., No. 21-CI-004833 (Ky. Cir. Ct.) (Jefferson Cnty). The court lifted a stay on October 30, 2023. Centene Corporation, Wellcare Healthcare Plans, Inc., New York Quality Healthcare Corp. (d/b/a Fidelis Care), and Health Net, LLC filed a complaint in the Circuit Court for the County of Roanoke, Virginia alleging similar claims on January 13, 2023. See Centene Corp. v. Indivior Inc., No. CL23000054-00 (Va. Cir. Ct.) (Roanoke Cnty). Indivior demurred to the complaint and asserted pleas in bar in early February 2024.

• Cases filed by (1) Blue Cross and Blue Shield of Massachusetts, Inc., Blue Cross and Blue Shield of Massachusetts HMO Blue, Inc., (2) Health Care Service Corp., (3) Blue Cross and Blue Shield of Florida, Inc., Health Options, Inc., (4) BCBSM, Inc. (d/b/a Blue Cross and Blue Shield of Minnesota) and HMO Minnesota (d/b/a Blue Plus), (5) Molina Healthcare, Inc., and (6) Aetna Inc. were filed in the Circuit Court for the County of Roanoke, Virginia. See Health Care Services Corp. v. Indivior Inc., No. CL20-1474 (Lead Case) (Va. Cir. Ct.) (Roanoke Cnty). In July 2023, Indivior Inc. and BCBSM, Inc. and HMO Minnesota agreed to mutual releases and settlement. The remaining plaintiffs asserted claims under federal and state RICO statutes, state antitrust statutes, state statutes prohibiting unfair and deceptive practices, state statutes prohibiting insurance fraud, and common law fraud, negligent misrepresentation, and unjust enrichment. The Group filed demurrers, which the court sustained in part and overruled in part. Separately, Indivior Inc. filed counterclaims against several plaintiffs alleging violations of certain insurance fraud statutes. The plaintiffs demurred. The court overruled HCSC's demurrer but sustained the demurrers of the remaining plaintiffs named in Indivior Inc.'s counterclaims. A jury trial on the Group's pleas in bar to the remaining plaintiffs' fraud claims was held on October 30 - November 3, 2023. The jury rendered a verdict finding that the plaintiffs' fraud claims are not barred by the statute of limitations. A jury trial on the merits has been set for July 15, 2024 - August 8, 2024.

• The Group is still in the process of evaluating the claims, believes it has meritorious defenses, and intends to defend itself. No estimate of the range of potential loss can be made at this time.

Civil Opioid Litigation

• The Group has been named as a defendant in more than 400 civil lawsuits alleging that manufacturers, distributors, and retailers of opioids engaged in a longstanding practice to market opioids as safe and effective for the treatment of long-term chronic pain to increase the market for opioids and their own market shares for opioids, or alleging individual personal injury claims. Most of these cases have been consolidated and are pending in a federal multidistrict litigation ("the Opioid MDL") in the U.S. District Court for the Northern District of Ohio. See In re National Prescription Opiate Litigation, MDL No. 2804 (N.D. Ohio). Nearly two-thirds of the cases in the Opioid MDL were filed by cities and counties, while nearly one-third of the cases were filed by individual plaintiffs, most of whom assert claims relating to neonatal abstinence syndrome ("NAS"). Litigation against the Group in the Opioid MDL is stayed. Motions to remand have been denied or withdrawn in more than 50 cases to which the Group is a party (among numerous other defendants). Motions to remand remain pending in additional cases to which the Group is a party.

• The court in the Opioid MDL has indicated that it does not expect to set additional bellwether trials involving county and municipality plaintiffs, provided that the parties are progressing on a settlement track. By order dated October 25, 2023, the Court selected four third-party payor (TPP) cases for bellwether trials. Indivior is not named as a defendant in any of the four TPP cases selected for bellwether trials.

• The court in the Opioid MDL has indicated that it does not intend to set additional bellwether trials for Tier 2 and Tier 3 manufacturer and distributor defendants, provided that those defendants remain actively engaged in mediation. The plaintiffs' executive committee indicated that it may seek leave to amend complaints to name additional defendants based on ARCOS data concerning opioid products. The court held a status conference on February 14, 2024, but did not rule on whether such amendment will be permitted.

• Regarding civil opioid cases not in the Opioid MDL:

◦ In 2017, Indivior Inc. was named as one of numerous defendants in International Brotherhood of Electrical Workers Local 728 Family Healthcare Plan v. Allergan, PLC et al., Case ID: 190303872 (C.P. Phila. Cnty). That case was consolidated with Lead Case No. 2017-008095 in Delaware County and stayed. The court held a hearing on September 29, 2023 regarding the status of settlement discussions and other issues in various groups of cases in the consolidated action. On December 29, 2023, the court issued an order remanding all third-party payor cases, including the case involving Indivior, back to the Philadelphia Court of Common Pleas. By agreement of the parties, objections to the complaints are due on February 26, 2024, or one week after the remand order is docketed, whichever is later.

◦ Indivior also was named as one of numerous defendants in various other federal and state court cases that are not in the Opioid MDL and were brought by municipalities. These cases include, for example, 35 actions filed in New York state court that were removed to federal court, as well as cases filed in federal district courts sitting in Alabama, Florida, and Georgia. The plaintiffs filed motions to remand the New York cases, which remain pending. The plaintiffs in the case filed in the Northern District of Alabama have voluntarily dismissed their complaint, subject to certain tolling agreements. The various other federal actions currently are stayed, and Indivior is not yet required to substantively respond to the complaints.

◦ Indivior Inc. was named as a defendant in five individual complaints filed in West Virginia state court that were transferred to West Virginia's Mass Litigation Panel. See In re Opioid Litigation, No. 22-C-9000 NAS (W.V. Kanawha Cnty. Cir. Ct.) ("WV MLP Action"). All five of Indivior Inc.'s cases in the WV MLP Action involved claims related to NAS. Indivior Inc. moved to dismiss all five complaints on January 30, 2023. By order dated April 17, 2023, the court granted Indivior's motions to dismiss. The plaintiffs filed a notice of appeal on June 30, 2023. Appellate briefing in the cases involving Indivior has been stayed.

• Given the status and preliminary stage of litigation in both the Opioid MDL and the separate federal and state court actions, no estimate of possible loss in the opioid litigation can be made at this time.

False Claims Act Allegations

• In August 2018, the United States District Court for the Western District of Virginia unsealed a declined qui tam complaint alleging causes of action under the Federal and state False Claims Acts against certain entities within the Group predicated on best price issues and claims of retaliation. See United States ex rel. Miller v. Reckitt Benckiser Group PLC et al., Case No. 1:15-cv-00017 (W.D. Va.). The suit also seeks reasonable attorneys' fees and costs. The Group filed a Motion to Dismiss in June 2021, which was granted in part and denied in part on October 17, 2023. The relator filed a sixth amended complaint against only Indivior Inc. on December 7, 2023. Indivior's deadline to respond to the sixth amended complaint is March 18, 2024.

• In May 2018, Indivior Inc. received an informal request from the United States Attorney's Office ("USAO") for the Southern District of New York, seeking records relating to the SUBOXONE Film manufacturing process. The Group provided the USAO certain information regarding allegations that the government received regarding SUBOXONE Film. There has been no communication regarding this matter with the USAO since 2022.

U.K. Shareholder Claims

• On September 21, 2022, certain shareholders issued representative and multiparty claims against Indivior PLC in the High Court of Justice for the Business and Property Courts of England and Wales, King's Bench Division. On January 16, 2023, the representative served its Particular of Claims setting forth in more detail the claims against the Group, while the same law firm that represents the representative also sent its draft Particular of Claims for the multiparty action. The claims made in both the representative and multiparty actions generally allege that Indivior PLC violated the U.K. Financial Services and Markets Act 2000 ("FSMA 2000") by making false or misleading statements or material omissions in public disclosures, including the 2014 Demerger Prospectus, regarding an alleged product-hopping scheme regarding the switch from SUBOXONE Tablets to SUBOXONE Film. Indivior PLC filed an application to strike out the representative action. On December 5, 2023, the court handed down a judgment allowing the Group's application to strike out the representative action. The court subsequently awarded certain costs to the Group. On January 23, 2024, the claimants requested permission to appeal the decision to the court of appeals.

• The Group has begun its evaluation of the claims, believes it has meritorious defenses, and intends to vigorously defend itself. Given the status and preliminary stage of the litigation, no estimate of possible loss can be made at this time.

Tooth Damage Allegations

• The Group has been named as a defendant in more than 30 lawsuits that have been consolidated into a multidistrict litigation in the Northern District of Ohio. See In Re Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation, MDL No. 3092 (N.D. Oh.). The plaintiffs generally allege that the Group failed to properly warn physicians of the risk of dental injury, and further allege that SUBOXONE products were defectively designed. The plaintiffs generally seek compensatory damages, as well as punitive damages and attorneys' fees and costs. On February 2, 2024, the Judicial Panel on Multidistrict Litigation entered an order establishing multidistrict litigation proceedings in the United States District Court for the Northern District of Ohio. Product liability cases such as these typically involve issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters. These cases are in their preliminary stages. The Group is evaluating the claims and its defenses, believes it has meritorious defenses, and intends to defend itself. No estimate of the range of potential loss can be made at this time. These lawsuits follow a June 2022 required revision to the Prescribing Information and Patient Medication Guide about dental problems reported in connection with buprenorphine medicines dissolved in the mouth to treat opioid use disorder. This revision was required by the FDA of all manufacturers of these products.
Posted at 23/1/2024 17:41 by pngasef
Amazing rebound in the share price, no doubt due to it being vastly oversold.
Posted at 20/12/2023 08:27 by adrian j boris
Indivior PLC Indivior Settles Patent Dispute with Actavis (3885X)
20/12/2023 7:00am
UK Regulatory (RNS & others)

Indivior (LSE:INDV)


RNS Number : 3885X

Indivior PLC

20 December 2023

Indivior Settles Patent Dispute with Teva Subsidiary Actavis

Richmond, VA and Slough UK, December 20, 2023 - Indivior PLC (LSE/NASDAQ: INDV) , a leading addiction treatment company, today announced that its subsidiaries Indivior Inc. and Indivior UK Limited (together, "Indivior") entered into a settlement agreement with Actavis Laboratories UT, Inc. ("Actavis"), a subsidiary of Teva Pharmaceuticals, to resolve patent disputes regarding Actavis's Abbreviated New Drug Application ("ANDA") for generic buprenorphine and naloxone sublingual film. Under the agreement, Indivior granted Actavis a license to U.S. Patent No. 11,135,216 that would enable Actavis to launch the generic film products identified in its ANDA in the United States no earlier than January 31, 2025, unless the unexpired patent claims are found invalid or unenforceable before that time in a final judicial decision.
Posted at 05/12/2023 16:08 by waldron
Indivior PLC INDV Prevails in Striking Claims in UK Litigation (7595V)
05/12/2023 2:06pm
UK Regulatory (RNS & others)

Tuesday 5 December 2023


RNS Number : 7595V

Indivior Prevails in Striking Representative Claims from UK Shareholder Action

Richmond, VA and Slough UK, December 5, 2023 - Indivior PLC (LSE/NASDAQ: INDV) , a leading addiction treatment company, announced that the High Court of Justice of England and Wales has issued a judgment striking out representative claims by Wirral Council as administering authority of Merseyside Pension fund ("Wirral") against Indivior under the Financial Services and Markets Act 2000 ("FSMA"). Wirral's suit was the first attempt by claimants to use representative proceedings for securities claims brought under Sections 90, 90A, and Schedule 10 of the FSMA. The proposed representative proceedings, if allowed, would permit a representative acting on behalf of unnamed claimants to attempt to prove a violation of law without proof of damages, in contrast to ordinary multi-party proceedings, which require proof of liability and damages for each claimant.

In September 2022, Wirral had filed a representative claim generally asserting that Indivior violated the FSMA by making misleading or dishonest statements regarding an alleged fraudulent scheme to switch the market for its SUBOXONE (R) branded products in published information relating to securities. A similar claim was filed against Reckitt Benckiser.

After hearing two days of argument in November 2023, the High Court on December 5 issued a judgment granting Indivior's and Reckitt Benckiser's applications to strike out the representative proceedings. The Court specifically found that it "would be unfair and unjust, and contrary to the overriding objective, to allow the Representative Proceedings to oust the jurisdiction of the Court to case manage the claims from the start." The Court's judgment may be found here .

Wirral and other claimants separately had filed a multi-party action generally alleging the same claims, and levied similar allegations against Reckitt Benckiser Group PLC ("Reckitt Benckiser") in separate actions. Pursuant to the Court's judgment, the claim against Indivior may only proceed in those multi-party proceedings brought by the claimants named in those proceedings.

Wirral may seek permission to appeal the Court's judgment.

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of substance use disorder (SUD). Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 1,000 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit to learn more. Connect with Indivior on LinkedIn by visiting

This release is being made by Kathryn Hudson, Company Secretary Indivior PLC.

Media Contacts :

US Media :

Cassie France-Kelly

Vice President, Communications

Indivior PLC

Tel: 804-724-0327

UK Media :


Tel: +44 207-353-4200

Investors and Analysts :

Jason Thompson

Vice President, Investor Relations

Indivior PLC

Tel: 804-402-7123

Tim Owens

Director, Investor Relations

Indivior PLC

Tel: 804-263-3978


(END) Dow Jones Newswires

December 05, 2023 09:06 ET (14:06 GMT)
Posted at 05/12/2023 16:04 by waldron
Indivior and Reckitt land legal boost in UK Suboxone claim

Tue, 05th Dec 2023 15:38
Alliance News

(Alliance News) - Indivior PLC and one-time parent Reckitt Benckiser Group PLC were handed a legal victory on Tuesday after the High Court of Justice of England & Wales dismissed a lawsuit related to alleged false marketing of an opioid addiction treatment.

Wirral Council, on behalf of Merseyside Pension fund, looked to bring a representative claim, alleging that Indivior made "misleading or dishonest statements" related to Suboxone-braded products.

"After hearing two days of argument in November 2023, the High Court on December 5 issued a judgment granting Indivior's and Reckitt Benckiser's applications to strike out the representative proceedings," Richmond, Virginia-based pharmaceutical firm Indivior said.

Indivior noted Wirral may seek the green light to appeal the court decision.

Back in October, Indivior said it has reached an agreement to settle a US multi-district Suboxone litigation case, forking out USD385 million in the process.

The litigation was centred on the claim that the pharmaceutical company stymied generic competition for the opioid addiction treatment Suboxone, in order to preserve its dominance.

The settlement marked the end of the multi-district litigation, once approved by the United States District Court for the Eastern District of Pennsylvania.

Indivior was formerly part of Reckitt Benckiser Group PLC, before being spun out in late 2014.

Indivior's share price was down 4.6% at 1,258.00 pence each in London on Tuesday afternoon. Reckitt fell 0.8% to 5,408.00p.

By Hugh Cameron, Alliance News reporter

Comments and questions to
Posted at 17/11/2023 15:43 by gregmorg
Yes today's announcements are positive and have probably steadied the shareholder boat- its a view! However read between the lines and just quite possibly one can start to comprehend what has been happening!

Also,there is a new biggish shareholder, Madison Partners LP . I say new as I cannot trace them as shareholders previously but do check, maybe that's me!

If it is a new shareholder then we haven't quite seen the full story yet as the stock has come from somewhere. I suspect today's announcements tell some of the story but not quite all. Could it possibly be Scopia's revised shareholding agreement has already been acted upon?

Whatever has been driving the recent share price weakness and the above maybe well wide of the mark!, today's statements on trading , prospects etc and the proposed major share buy back program have reassured me in quite a big way. Doesn't mean to say I am right!
Posted at 12/3/2022 17:05 by typo56
The news is quite possibly a continuation of this from 23 Feb..

"Indivior, the FTSE 250-listed opiod addiction treatment company, is rumoured to be the mystery bidder circling Opiant Pharmaceuticals, the US-listed developer of medicines for drug addiction.

People following the situation have heard rumours Indivior has been talking to Opiant since December last year year about a possible offer for the company."

Good or bad for the INDV share price? You decide!
Posted at 15/1/2021 17:52 by grupo guitarlumber
Indivior is the biggest FTSE 250 gainer today. Would I buy it now?

Manika Premsingh | Friday, 15th January, 2021

Business development to success and FTSE 100 250 350 growth concept.

The FTSE 250 opioid addiction treatment provider Indivior (LSE: INDV) is the biggest index gainer today as I write. Its share price is up 9%, continuing its recovery after a sharp fall in late November.

Why the share price rose

INDV’s better-than-expected financial results are the clear reason for the uptick in share price. It now expects revenue to be at least $25m higher than it had expected earlier for the full year. It also expects expenses to be lower, resulting in an improved income forecast.

What’s next for the INDV share price

I reckon that the latest news will provide continued impetus for INDV’s share price. It’s now at 115p, up from the sub-100p levels it was at before the last week of December. The big decline started in late November, when it crashed 30% in a day following news that its former parent company — Reckitt Benckiser — had filed a £1bn claim on it.

Even now the share price is still much lower than its 131p levels at the time. But at least it’s now closer than ever to getting back there.

When I last wrote about Indivior, after its share price fall, my sense was that its share price would be dependent more on its own performance than anything else. If the share price reaction to its latest results is anything to go by, it only proves the point I was making at the time. If its performance remains consistent, I reckon that its share price can climb up further.

This is especially so in today’s bullish market, where investors are rewarding companies that are performing well.

Battling the opioid crisis

Moreover, the seriousness of the opioid crisis is big and rising, an issue that Indivior is well placed to address. According to the World Health Organisation, globally 0.5m deaths are caused by drug use every year, of which 70% are opioid-related. Moreover, between 2010 and 2018, the number of people dying of opioid overdose in the US increased by 120%.

Past problems still haunt

Despite this, as an investor I’m cautious because of INDV’s problems from the recent past, which include accusations of mis-selling and resulted in its former CEO being imprisoned. Almost two months after I wrote about INDV, it indeed appears to have put the episode behind it. It has also said that Reckitt Benckiser’s claim is without merit.

Further, its financials had suffered quite the blow in the first nine months of 2020, with a sharp decline in revenue. The latest numbers, then, are a surprise development and not one that reflects the inherent, ongoing strength of the company.

I think the INDV stock looks much better after its results than it did two months ago when it was far more in the thick of a crisis. It could continue to see improvements from here. But I really want to see some more predictability to its financials before buying the stock.

Manika Premsingh has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned.
Indivior share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |